Last updated: April 30, 2026
Gilead v. Teva (1:10-cv-01796): Litigation Summary and Patent/Remedy Posture
What is the case and what parties are involved?
Case: Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., 1:10-cv-01796
Parties:
- Plaintiff: Gilead Sciences, Inc.
- Defendant: Teva Pharmaceuticals USA, Inc.
Where is the case filed and what type of dispute is it?
The case is a federal patent litigation matter. The Docket number pattern (1:10-cv-01796) indicates a civil action in U.S. District Court, brought by a patent holder against a generic applicant/manufacturer. The litigation is analyzed as a patent-infringement and/or Hatch-Waxman-style challenge tied to an ANDA product entry based on standard structure of Gilead v. Teva disputes in the same time period.
What is the asserted patent landscape?
The record provided in this prompt does not include the specific asserted patent numbers, claims, the drug/ANDA reference, the infringement theory, or the validity challenges. Under the operating constraint, this prevents a complete and accurate litigation analysis (including how the patents map to product and what was held).
What did the court do procedurally (high-level)?
No docket events, claim construction outcomes, summary judgment rulings, trial outcomes, or injunction/remedy dispositions are included in the information provided in this prompt. Without those entries, an accuracy-complete timeline cannot be produced.
What was the end result (judgment, injunction, damages, licensing)?
No final disposition details are included (for example, final judgment, consent judgment, stipulated dismissal, or appellate disposition). Without docket-level final orders, remedy and scope conclusions cannot be stated.
Why this matters for freedom-to-operate and launch timing
In Gilead v. Teva drug-patent disputes of this vintage, the operational impact typically flows from three decision points:
- Whether key claims are found infringed
- Whether key claims are held valid
- Whether the court grants an injunction or instead resolves via non-infringement/invalidity findings
But the necessary facts for this specific docket (the patents, claims, and final holdings) are not present in the prompt, so the case cannot be translated into enforceability, launch timing, or risk scoring with accuracy.
Actionable Litigation Framework (What to extract from the docket once known)
The following elements are the minimum set required to convert the litigation into decision-grade R&D and investment implications:
| Decision input |
Needed docket item |
Why it drives outcomes |
| Asserted patents |
Patent numbers + publication/application chain |
Determines expiry, PTA, and continuation risk |
| Claim scope |
Claim construction order or chart |
Controls infringement map and design-around feasibility |
| Infringement theory |
Element-by-element infringement allegations |
Determines likelihood for product redesign |
| Validity posture |
Invalidity contentions and claim-by-claim rulings |
Controls whether the asserted claims survive |
| Remedy |
Injunction order and any carve-outs |
Sets launch timing and entry conditions |
| Procedural end |
Final judgment order and any appellate stay |
Determines enforceability duration and collateral impact |
This framework is relevant because it is the exact structure courts and litigants use to convert filings into enforceability and business decisions.
Key Takeaways
- Case identified: Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., 1:10-cv-01796.
- Complete patent-and-remedy analysis cannot be produced from the information provided in this prompt because the asserted patents, claims, and dispositive rulings are not included.
- For decision-grade use, the docket must supply the asserted patent numbers, claim constructions, and final judgment terms.
FAQs
-
What drug is the case about?
The drug and ANDA/RLD linkage are not specified in the provided prompt.
-
Which patents did Gilead assert in 1:10-cv-01796?
The asserted patent numbers are not provided in the prompt.
-
Did the court grant an injunction?
Injunction outcome is not included in the prompt.
-
Was the case dismissed, settled, or decided on the merits?
The final procedural disposition is not included in the prompt.
-
What is the business impact for generic entry?
Business impact depends on the specific infringement/validity holdings and any injunction terms, which are not included in the prompt.
References
- None provided in the prompt.
